European Journal of Cancer
Volume 42, Issue 1 , Pages 42-49 , January 2006

Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?

  • Fabio Efficace

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), EORTC Data Center, Quality of Life Unit, Avenue E. Mounier, 83, 1200 Brussels, Belgium
    • Corresponding Author InformationCorresponding author: Tel.: +32 2 774 1680; fax: +32 2 779 4568.
    • ,
  • Andrew Bottomley

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), EORTC Data Center, Quality of Life Unit, Avenue E. Mounier, 83, 1200 Brussels, Belgium
    • ,
  • Corneel Coens

      Affiliations

    • European Organisation for Research and Treatment of Cancer (EORTC), EORTC Data Center, Quality of Life Unit, Avenue E. Mounier, 83, 1200 Brussels, Belgium
    • ,
  • Kristel Van Steen

      Affiliations

    • Harvard School of Public Health, Department of Biostatistics, Boston, USA
    • ,
  • Thierry Conroy

      Affiliations

    • Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France
    • ,
  • Patrick Schöffski

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • ,
  • Hans Schmoll

      Affiliations

    • Martin Luther Universitaet, Halle, Germany
    • ,
  • Eric Van Cutsem

      Affiliations

    • University Hospital Leuven, Leuven, Belgium
    • ,
  • Claus-Henning Köhne

      Affiliations

    • Klinikum Oldenburg, Oldenburg, Germany

Received 29 June 2005 ,Accepted 5 July 2005.

References 

  1. Stewart BW, Kleihues P. World Health Organization. World Cancer Report. Lyon: IARC Press; 2003;
  2. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer. 1993;29A:2077–2079
  3. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308–317
  4. Glare P, Virik K, Jones M, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327:195
  5. Efficace F, Biganzoli L, Piccart M, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004;40:1021–1030
  6. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;31:233–240
  7. Chiarion-Sileni V, Del Bianco P, De Salvo GL, et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer. 2003;39:1577–1585
  8. Collette L, van Andel G, Bottomley A, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 2004;22:3877–3885
  9. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–2403
  10. Earlam S, Glover C, Fordy C, et al. Relation between tumour size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171–175
  11. Maisey NR, Norman A, Watson M, et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–1357
  12. Van Steen K, Curran D, Kramer J, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med. 2002;21:3865–3884
  13. Köhne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003;21:3721–3728
  14. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  15. Hakamies-Blomqvist L, Luoma ML, Sjostrom J, et al. Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs. 2001;35:709–716
  16. Fayers P, Aaronson N, Bjordal K, et al. EORTC QLQ-C30 scoring manual. 3rd ed.. Brussels: EORTC Publications; 2001;
  17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  18. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc. 1937;32:675–701
  19. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;4:187–220
  20. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–1723
  21. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093–2109
  22. Augustin NH, Sauerbrei W, Schumacher M. Incorporating model selection into prognostic factor model predictions. Freiburg Center for Data Analysis and Modeling, Preprint nr 76; 2002. Available from: http://www.fdm.uni-freiburg.de/pub/preprints.php.
  23. Schumacher M, Hollander N, Sauerbrei W. Resampling and crossvalidation techniques: a tool to reduce bias caused by model building?. Stat Med. 1997;16:2813–2827
  24. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13:2936–2943
  25. Thirion P, Piedbois P, Buyse M, et al. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer. 2001;84:611–620
  26. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  27. Langendijk H, Aaronson NK, de Jong JM, et al. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol. 2000;55:19–25
  28. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol. 2003;21:673–678
  29. Fang FM, Liu YT, Tang Y, et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer. 2004;100:425–432
  30. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294–1303
  31. Arndt V, Merx H, Stegmaier C, et al. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol. 2004;22:4777–4784
  32. Coates AS, Hurny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol. 2000;18:3768–3774
  33. Efficace F, Bottomley A. Towards a clearer understanding of the prognostic value of health-related quality of life (HRQOL) parameters in breast cancer. J Clin Oncol. 2005;23:1335–1336

PII: S0959-8049(05)00846-4

doi: 10.1016/j.ejca.2005.07.025

European Journal of Cancer
Volume 42, Issue 1 , Pages 42-49 , January 2006

Article Tools